Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
The combined company now has an expanded pipeline that includes multiple assets from its adeno-associated virus (AAV)-based gene therapy portfolio, which is currently being developed for IRDs, as well as Phentolamine Ophthalmic Solution 0.75%, which is currently being evaluated in presbyopia and dim (mesopic) light vision disturbances (sometimes referred to as DLD) after keratorefractive surgery.On Wednesday, Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).
週三，可口可樂製藥公司（納斯達克股票代碼：OCUP）宣佈全股票收購臨床階段基因治療公司Opus Genetics，該公司專注於遺傳性視網膜疾病（IRDs）。
The merger creates a biotech company focused on developing gene therapies for IRDs.
合併將打造一家專注於開發IRDs基因治療的生物技術公司。
The combined company will be renamed Opus Genetics, effective October 23, 2024, and trade on the Nasdaq under the "IRD" ticker, effective October 24, 2024.
合併後的公司將於2024年10月23日更名爲Opus Genetics，並於2024年10月24日起在納斯達克交易，交易代碼爲「IRD」。
The combined company now has an expanded pipeline that includes multiple assets from its adeno-associated virus (AAV)-based gene therapy portfolio, which is currently being developed for IRDs, as well as Phentolamine Ophthalmic Solution 0.75%, which is currently being evaluated in presbyopia and dim (mesopic) light vision disturbances (sometimes referred to as DLD) after keratorefractive surgery.
合併後的公司現在擁有擴展的產品線，包括來自其基於腺相關病毒（AAV）的基因治療組合的多種資產，目前正在爲IRDs開發，以及Phentolamine眼科溶液0.75%，目前正在評估其用於老視和屈光手術後的暗光（mesopic）視力障礙（有時稱爲DLD）。
Due to the capital requirements and developmental timelines of APX3330 for non-proliferative diabetic retinopathy, the company will seek a partner to advance the clinical development of the late-stage diabetic retinopathy program. It will redirect its existing resources toward the acquired gene therapy programs.
由於非增殖性糖尿病視網膜病的APX3330的資金需求和發展時間表，該公司將尋找合作伙伴推進晚期糖尿病視網膜病項目的臨床開發。它將重新調配現有資源用於收購的基因治療項目。
The most advanced gene therapy candidate, OPGx-LCA5, is being developed for LCA5, an early-onset retinal degeneration, and an open-label, dose-escalation Phase 1/2 trial is ongoing.
最先進的基因治療候選藥OPGx-LCA5正在爲早發性視網膜退化症LCA5開發，正在進行開放標籤的劑量遞增1/2期臨床試驗。
The trial has shown early clinical proof-of-concept, with new six-month data demonstrating visual improvement in three out of three adult patients participating in the trial.
該試驗已顯示出早期臨床概念驗證，最新六個月的數據顯示，在參與試驗的三名成年患者中有三名出現視覺改善。
The first pediatric patients in the Phase 1/2 trial are expected to be enrolled in the first quarter of 2025, and the first data are anticipated in the first quarter of 2025.
預計2025年第一季度將招募第一批參與1/2期試驗的兒童患者，並預計2025年第一季度發佈首批數據。
The expected cash runway of the combined company has been extended into 2026.
合併公司的預期現金推出時間已延長至2026年。
Ocuphire issued 5.2 million shares and 14.1 thousand shares of its convertible preferred stock.
Ocuphire發行了520萬股普通股和1.41萬股可轉換優先股。
Following the issuances, Ocuphire will own approximately 58% of the combined company, and Opus Genetics will own approximately 42%.
在發行後，Ocuphire將擁有合併公司約58%的股份，而Opus Genetics將擁有約42%。
Price Action: OCUP stock is down 13.5% at $1.15 at last check Wednesday.
股價走勢：OCUP股價在上週三最後交易時下跌了13.5%，爲1.15美元。
- Coca-Cola Q3 Earnings: EPS Beat, Pricing Growth Offset By Volume Decline, Sees 10% Q4 Organic Revenue Growth.
- 可口可樂第三季度收益：每股收益超過預期，價格增長被銷量下降抵消，預計第四季度有機營業收入增長10%。
Photo via Wikimedia Commons
照片通過Wikimedia Commons
